{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:46:12Z","timestamp":1778640372561,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T00:00:00Z","timestamp":1436227200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["Grant code:IG-10092"],"award-info":[{"award-number":["Grant code:IG-10092"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["Grant code:IG-14249"],"award-info":[{"award-number":["Grant code:IG-14249"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009882","name":"Regione Lombardia","doi-asserted-by":"crossref","award":["Grant code:ID-16871"],"award-info":[{"award-number":["Grant code:ID-16871"]}],"id":[{"id":"10.13039\/501100009882","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["Grant code:ID14546A"],"award-info":[{"award-number":["Grant code:ID14546A"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Regione Lombardia - FSE","award":["Grant code:ID 16-AR"],"award-info":[{"award-number":["Grant code:ID 16-AR"]}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Grant code:RFPS-2006-333974"],"award-info":[{"award-number":["Grant code:RFPS-2006-333974"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13045-015-0179-4","type":"journal-article","created":{"date-parts":[[2015,7,6]],"date-time":"2015-07-06T09:51:10Z","timestamp":1436176270000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib"],"prefix":"10.1186","volume":"8","author":[{"given":"Sara","family":"Redaelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Perini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Ceccon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Rigolio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Mauri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Boschelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athina","family":"Giannoudis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Gambacorti-Passerini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,7]]},"reference":[{"key":"179_CR1","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/S1470-2045(08)70152-9","volume":"9","author":"C Gambacorti-Passerini","year":"2008","unstructured":"Gambacorti-Passerini C. Part I: milestones in personalised medicine--imatinib. Lancet Oncol. 2008;9:600.","journal-title":"Lancet Oncol"},{"key":"179_CR2","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim D-W, Issaragrisil S, Le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"179_CR3","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370.","journal-title":"N Engl J Med"},{"key":"179_CR4","doi-asserted-by":"crossref","unstructured":"Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L, et al. (2012) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 30: 3486-3492.","DOI":"10.1200\/JCO.2011.38.7522"},{"key":"179_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","volume":"4","author":"CB Gambacorti-Passerini","year":"2003","unstructured":"Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 2003;4:75\u201385.","journal-title":"Lancet Oncol"},{"key":"179_CR6","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004;104:3739\u201345.","journal-title":"Blood"},{"key":"179_CR7","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1124\/jpet.103.055574","volume":"307","author":"A Hamada","year":"2003","unstructured":"Hamada A, Miyano H, Watanabe H, Saito H. Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther. 2003;307:824\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"179_CR8","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","volume":"104","author":"H Burger","year":"2004","unstructured":"Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump. Blood. 2004;104:2940\u20132.","journal-title":"Blood"},{"key":"179_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/10915810600746023","volume":"25","author":"S Choudhuri","year":"2006","unstructured":"Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol. 2006;25:231\u201359.","journal-title":"Int J Toxicol"},{"key":"179_CR10","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1182\/blood-2012-01-405035","volume":"121","author":"A Giannoudis","year":"2013","unstructured":"Giannoudis A, Wang L, Jorgensen AL, Xinarianos G, Davies A, Pushpakom S, et al. The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood. 2013;121:628\u201337.","journal-title":"Blood"},{"key":"179_CR11","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","volume":"108","author":"DL White","year":"2006","unstructured":"White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006;108:697\u2013704.","journal-title":"Blood"},{"key":"179_CR12","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1182\/blood-2007-10-116236","volume":"112","author":"A Giannoudis","year":"2008","unstructured":"Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood. 2008;112:3348\u201354.","journal-title":"Blood"},{"key":"179_CR13","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1038\/leu.2009.166","volume":"23","author":"A Davies","year":"2009","unstructured":"Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ, et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia. 2009;23:1999\u20132006.","journal-title":"Leukemia"},{"key":"179_CR14","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/clpt.2013.208","volume":"95","author":"LN Eadie","year":"2014","unstructured":"Eadie LN, Hughes TP, White DL. Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. Clin Pharmacol Ther. 2014;95:294\u2013306.","journal-title":"Clin Pharmacol Ther"},{"key":"179_CR15","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","volume":"14","author":"DK Hiwase","year":"2008","unstructured":"Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res. 2008;14:3881\u20138.","journal-title":"Clin Cancer Res"},{"key":"179_CR16","doi-asserted-by":"crossref","unstructured":"Gromicho M, Dinis J, Magalhaes M, Fernandes AR, Tavares P, Laires A, et al. (2011) Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leuk Lymphoma 52: 1980-1990.","DOI":"10.3109\/10428194.2011.584005"},{"key":"179_CR17","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567\u201376.","journal-title":"Blood"},{"key":"179_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1124\/dmd.32.5.519","volume":"32","author":"N Ishiguro","year":"2004","unstructured":"Ishiguro N, Nozawa T, Tsujihata A, Saito A, Kishimoto W, Yokoyama K, et al. Influx and efflux transport of H1-antagonist epinastine across the blood-brain barrier. Drug Metab Dispos. 2004;32:519\u201324.","journal-title":"Drug Metab Dispos"},{"key":"179_CR19","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0022-3565(24)37595-0","volume":"286","author":"L Zhang","year":"1998","unstructured":"Zhang L, Schaner ME, Giacomini KM. Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998;286:354\u201361.","journal-title":"J Pharmacol Exp Ther"},{"key":"179_CR20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/leu.2010.7","volume":"24","author":"L Eadie","year":"2010","unstructured":"Eadie L, Hughes TP, White DL. Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells. Leukemia. 2010;24:855\u20137.","journal-title":"Leukemia"},{"key":"179_CR21","doi-asserted-by":"publisher","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","volume":"66","author":"M Puttini","year":"2006","unstructured":"Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl\u2009+\u2009neoplastic cells. Cancer Res. 2006;66:11314\u201322.","journal-title":"Cancer Res"},{"key":"179_CR22","unstructured":"Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, et al. (2003) SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63:375-381."},{"key":"179_CR23","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"S Branford","year":"2002","unstructured":"Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;99:3472\u20135.","journal-title":"Blood"},{"key":"179_CR24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876\u201380.","journal-title":"Science"},{"key":"179_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cancergencyto.2005.05.004","volume":"163","author":"A Ossard-Receveur","year":"2005","unstructured":"Ossard-Receveur A, Bernheim A, Clausse B, Danglot G, Fauvet D, Leon B, et al. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia. Cancer Genet Cytogenet. 2005;163:189\u201390.","journal-title":"Cancer Genet Cytogenet"},{"key":"179_CR26","doi-asserted-by":"crossref","unstructured":"Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, et al. (2003) Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 101: 3794-3800.","DOI":"10.1182\/blood-2002-09-2790"},{"key":"179_CR27","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/jnci\/92.20.1641","volume":"92","author":"C Gambacorti-Passerini","year":"2000","unstructured":"Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst. 2000;92:1641\u201350.","journal-title":"J Natl Cancer Inst"},{"key":"179_CR28","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496\u20139.","journal-title":"Blood"},{"key":"179_CR29","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.leukres.2007.08.009","volume":"32","author":"I Jilani","year":"2008","unstructured":"Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, et al. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. Leuk Res. 2008;32:643\u20139.","journal-title":"Leuk Res"},{"key":"179_CR30","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.ejca.2009.04.005","volume":"45","author":"E San Jose-Eneriz","year":"2009","unstructured":"San Jose-Eneriz E, Agirre X, Jimenez-Velasco A, Cordeu L, Martin V, Arqueros V, et al. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer. 2009;45:1877\u201389.","journal-title":"Eur J Cancer"},{"key":"179_CR31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4149\/neo_2009_03_202","volume":"56","author":"K Czyzewski","year":"2009","unstructured":"Czyzewski K, Styczynski J. Imatinib is a substrate for various multidrug resistance proteins. Neoplasma. 2009;56:202\u20137.","journal-title":"Neoplasma"},{"key":"179_CR32","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","volume":"158","author":"C Hegedus","year":"2009","unstructured":"Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009;158:1153\u201364.","journal-title":"Br J Pharmacol"},{"key":"179_CR33","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/sj.leu.2404897","volume":"22","author":"S Shukla","year":"2008","unstructured":"Shukla S, Sauna ZE, Ambudkar SV. Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Leukemia. 2008;22:445\u20137.","journal-title":"Leukemia"},{"key":"179_CR34","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","volume":"14","author":"S Hu","year":"2008","unstructured":"Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, et al. Interaction of imatinib with human organic ion carriers. Clin Cancer Res. 2008;14:3141\u20138.","journal-title":"Clin Cancer Res"},{"key":"179_CR35","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/leu.2010.16","volume":"24","author":"JR Engler","year":"2010","unstructured":"Engler JR, Frede A, Saunders VA, Zannettino AC, Hughes TP, White DL. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia. 2010;24:765\u201370.","journal-title":"Leukemia"},{"key":"179_CR36","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1016\/S0960-894X(03)00628-0","volume":"13","author":"DH Boschelli","year":"2003","unstructured":"Boschelli DH, Powell D, Golas JM, Boschelli F. Inhibition of Src kinase activity by 4-anilino-5,10-dihydro-pyrimido[4,5-b]quinolines. Bioorg Med Chem Lett. 2003;13:2977\u201380.","journal-title":"Bioorg Med Chem Lett"},{"key":"179_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0014-2999(97)01548-3","volume":"343","author":"S Mankhetkorn","year":"1998","unstructured":"Mankhetkorn S, Garnier-Suillerot A. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake. Eur J Pharmacol. 1998;343:313\u201321.","journal-title":"Eur J Pharmacol"},{"key":"179_CR38","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.exphem.2005.03.014","volume":"33","author":"H Rumpold","year":"2005","unstructured":"Rumpold H, Wolf AM, Gruenewald K, Gastl G, Gunsilius E, Wolf D. RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp Hematol. 2005;33:767\u201375.","journal-title":"Exp Hematol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-015-0179-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-015-0179-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-015-0179-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-015-0179-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T01:34:54Z","timestamp":1748482494000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-015-0179-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,7]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["179"],"URL":"https:\/\/doi.org\/10.1186\/s13045-015-0179-4","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,7]]},"assertion":[{"value":"3 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"81"}}